It Sounded Like a Good Idea at the Time

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 12, 2012, Pages 1127-1130

  Tone, Alicia ^a   McAlpine, Jessica ^a   Finlayson, Sarah ^a   Blake Gilks, C ^a   Heywood, Mark ^a   Huntsman, David ^a   Miller, Dianne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANADA; CANCER GRADING; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HUMAN; HYSTERECTOMY; INFORMED CONSENT; LETTER; MEDICAL SOCIETY; OVARY CARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; RISK REDUCTION; SALPINGECTOMY; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UTERINE TUBE LIGATION; NOTE; OVARY TUMOR;

FEMALE; HUMANS; OVARIAN NEOPLASMS; SALPINGECTOMY;

EID: 84907186203     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35456-1     Document Type: Letter

References (40)

1. Thiel J. It sounded like a good idea at the time. J Obstet Gynaecol Can 2012, 34(7):611-612.
2. Tone A.A., Salvador S., Finlayson S.J., Tinker A.V., Kwon J.S., Lee C.H., et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012, 10(5):296-306.
3. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007, 31(2):161-169.
4. Salvador S., Rempel A., Soslow R.A., Gilks B., Huntsman D., Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 2008, 110(3):408-417.
5. Carlson J.W., Miron A., Jarboe E.A., Parast M.M., Hirsch M.S., Lee Y., et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008, 26(25):4160-4165.
6. Roh M.H., Kindelberger D., Crum C.P. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?. Am J Surg Pathol 2009, 33(3):376-383.
7. Przybycin C.G., Kurman R.J., Ronnett B.M., Shih Ie M., Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am J Surg Pathol 2010, 34(10):1407-1416.
8. Seidman J.D., Zhao P., Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011, 120(3):470-473.
9. Colgan T.J., Murphy J., Cole D.E., Narod S., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001, 25(10):1283-1289.
10. Leeper K., Garcia R., Swisher E., Goff B., Greer B., Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002, 87(1):52-56.
11. Cass I., Holschneider C., Datta N., Barbuto D., Walts A.E., Karlan B.Y. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol 2005, 106(6):1327-1334.
12. Finch A., Shaw P., Rosen B., Murphy J., Narod S.A., Colgan T.J. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006, 100(1):58-64.
13. Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006, 30(2):230-236.
14. Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A., Garber J.E., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007, 25(25):3985-3990.
15. Shaw P.A., Rouzbahman M., Pizer E.S., Pintilie M., Begley H. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009, 22(9):1133-1138.
16. Powell C.B., Chen L.M., McLennan J., Crawford B., Zaloudek C., Rabban J.T., et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011, 21(5):846-851.
17. Yates M.S., Meyer L.A., Deavers M.T., Daniels M.S., Keeler E.R., Mok S.C., et al. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 2011, 4(3):463-470.
18. Folkins A.K., Jarboe E.A., Roh M.H., Crum C.P. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol 2009, 113(3):391-396.
19. Agoff S.N., Garcia R.L., Goff B., Swisher E. Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol 2004, 28(8):1112-1114.
20. Brown P.O., Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009, 6(7):e1000114.
21. Kobayashi H., Yamada Y., Sado T., Sakata M., Yoshida S., Kawaguchi R., et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008, 18(3):414-420.
22. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10(4):327-340.
23. Buys S.S., Partridge E., Greene M.H., Prorok P.C., Reding D., Riley T.L., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005, 193(5):1630-1639.
24. Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305(22):2295-2303.
25. Tone A.A., Huntsman D.G., Miller D.M. Screening of symptomatic women for ovarian cancer. Lancet Oncol 2012, 13(4):e137-e138. author reply e9-40.
26. GOC Statement Regarding Salpingectomy and Ovarian Cancer Prevention 2011, Available at:, Accessed October 10, 2012. http://www.g-o-c.org/uploads/11sept15_gocevidentiarystatement_final_en.pdf.
27. Tung K.H., Goodman M.T., Wu A.H., McDuffie K., Wilkens L.R., Kolonel L.N., et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003, 158(7):629-638.
28. Rice M.S., Murphy M.A., Tworoger S.S. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res 2012, 5(1):13.
29. Dietl J., Wischhusen J., Hausler S.F. The post-reproductive fallopian tube:better removed?. Hum Reprod 2011, 26(11):2918-2924.
30. McAlpine J.N., Porter H., Kobel M., Nelson B.H., Prentice L.M., Kalloger S.E., et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012, 25:740-750.
31. Schrader K.A., Hurlburt J., Kalloger S.E., Hansford S., Young S., Huntsman D.G., et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol 2012, 120(2 Pt 1):235-240.
32. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346(21):1609-1615.
33. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003, 88(1 Pt 2):S8-S10. discussion S1-3.
34. Finch A., Beiner M., Lubinski J., Lynch H.T., Moller P., Rosen B., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006, 296(2):185-192.
35. DeStefano F., Huezo C.M., Peterson H.B., Rubin G.L., Layde P.M., Ory H.W. Menstrual changes after tubal sterilization. Obstet Gynecol 1983, 62(6):673-681.
36. Verhulst G., Vandersteen N., van Steirteghem A.C., Devroey P. Bilateral salpingectomy does not compromise ovarian stimulation in an in-vitro fertilization/embryo transfer programme. Hum Reprod 1994, 9(4):624-628.
37. Strandell A., Lindhard A., Waldenstrom U., Thorburn J., Janson P.O., Hamberger L. Hydrosalpinx and IVF outcome: a prospective, randomized multicentre trial in Scandinavia on salpingectomy prior to IVF. Hum Reprod 1999, 14(11):2762-2769.
38. Dar P., Sachs G.S., Strassburger D., Bukovsky I., Arieli S. Ovarian function before and after salpingectomy in artificial reproductive technology patients. Hum Reprod 2000, 15(1):142-144.
39. Strandell A., Lindhard A., Waldenstrom U., Thorburn J. Prophylactic salpingectomy does not impair the ovarian response in IVF treatment. Hum Reprod 2001, 16(6):1135-1139.
40. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?. Gynecol Oncol 1999, 72(3):437-442.